The UK and US have concluded a landmark bilateral deal that will guarantee zero levies on UK medicine products being sold in the American market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has pledged to raise funding on medicines through the NHS. This pledge secures that import taxes on these crucial exports will be held at nothing for a period of three years.
This deal follows recent warnings to hike duties on patented drug imports, with potential rates mentioned as high as 100%.
"This agreement between the United Kingdom bolsters the international landscape for new treatments and establishes much-needed equity to transatlantic pharmaceutical trade," a release noted.
Trade Impact
Medicines represent one of the UK's biggest goods shipped to the United States, which is by far the largest buyer for large British pharmaceutical firms.
Trade data indicate that in the one-year period prior to the third quarter, the UK shipped drugs valued at billions to the US. This value represented a significant portion of all goods exports in that period.
"This deal secures work, stimulates investment and facilitates the UK to become a worldwide center for life sciences," a minister remarked.
Detailed British Pledges
The pact includes several notable changes from the British government:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it considers new therapies to be unaffordable by a quarter.
- Higher Drug Budget: There is a goal to increase overall NHS spending on treatments from 0.3% of GDP to 0.6% over the next decade.
- Rebate Cap: The percentage pharmaceutical firms must refund to the NHS to stay within budget will be limited at fifteen percent. Previously, repayments exceeded 20%.
Broader Context
The deal follows a protracted tension between the sector and the UK government over drug pricing and regulatory access.
This friction were heightened by arguments that American patients were paying a premium for the equivalent treatments than people in the Britain and the EU.
Over the last 18 months, several major drug company projects in the UK have been delayed or scrapped, while major funding commitments have been announced toward American operations.
One official acknowledged that the NHS must increase expenditure on treatments, noting that its expenditure on drugs had shrunk as a proportion of its resources over the previous ten-year period.
